Haemonetics Company Profile (NYSE:HAE)

About Haemonetics (NYSE:HAE)

Haemonetics logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:HAE
  • CUSIP: 40502410
  • Web: www.haemonetics.com
Capitalization:
  • Market Cap: $2.09 billion
  • Outstanding Shares: 51,990,000
Average Prices:
  • 50 Day Moving Avg: $41.40
  • 200 Day Moving Avg: $39.78
  • 52 Week Range: $27.52 - $43.62
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 22.29
  • P/E Growth: 3.31
Sales & Book Value:
  • Annual Revenue: $886.12 million
  • Price / Sales: 2.35
  • Book Value: $14.23 per share
  • Price / Book: 2.82
Profitability:
  • EBIDTA: $146.34 million
  • Net Margins: 1.79%
  • Return on Equity: 10.51%
  • Return on Assets: 5.89%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 2.30%
  • Quick Ratio: 1.42%
Misc:
  • Average Volume: 309,474 shs.
  • Beta: 0.92
  • Short Ratio: 9.18
 

Frequently Asked Questions for Haemonetics (NYSE:HAE)

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) released its earnings results on Monday, May, 8th. The company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.02. The business had revenue of $228.10 million for the quarter, compared to the consensus estimate of $215.06 million. Haemonetics had a return on equity of 10.51% and a net margin of 1.79%. Haemonetics's quarterly revenue was down 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.37 earnings per share. View Haemonetics' Earnings History.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY18 earnings guidance on Monday, May, 8th. The company provided EPS guidance of $1.55-1.65 for the period, compared to the Thomson Reuters consensus estimate of $1.59. The company issued revenue guidance of to approximate FY17 of $886.1 million, compared to the consensus revenue estimate of $899.98 million.

Where is Haemonetics' stock going? Where will Haemonetics' stock price be in 2017?

7 equities research analysts have issued 1 year price targets for Haemonetics' shares. Their forecasts range from $24.00 to $42.00. On average, they anticipate Haemonetics' share price to reach $35.83 in the next year. View Analyst Ratings for Haemonetics.

Who are some of Haemonetics' key competitors?

Who owns Haemonetics stock?

Haemonetics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.09%), Vanguard Group Inc. (9.03%), Wellington Management Group LLP (8.06%), Wells Fargo & Company MN (4.90%), Victory Capital Management Inc. (4.60%) and Neuberger Berman Group LLC (3.86%). Company insiders that own Haemonetics stock include Brian Concannon, Byron Selman, Christopher J Lindop, Christopher Simon, Jonathan White, Peter M Allen, Ronald G Gelbman, Ronald Merriman, Sandra Jesse and Susan M Hanlon. View Institutional Ownership Trends for Haemonetics.

Who sold Haemonetics stock? Who is selling Haemonetics stock?

Haemonetics' stock was sold by a variety of institutional investors in the last quarter, including Cornerstone Capital Management Holdings LLC., FMR LLC, Heartland Advisors Inc., Morgan Stanley, JPMorgan Chase & Co., Renaissance Technologies LLC, North Star Asset Management Inc. and BTIM Corp.. Company insiders that have sold Haemonetics stock in the last year include Ronald G Gelbman and Ronald Merriman. View Insider Buying and Selling for Haemonetics.

Who bought Haemonetics stock? Who is buying Haemonetics stock?

Haemonetics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, Columbia Wanger Asset Management LLC, Vanguard Group Inc., Black Creek Investment Management Inc., Victory Capital Management Inc., Parametric Portfolio Associates LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Haemonetics.

How do I buy Haemonetics stock?

Shares of Haemonetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Haemonetics stock cost?

One share of Haemonetics stock can currently be purchased for approximately $40.13.

Analyst Ratings

Consensus Ratings for Haemonetics (NYSE:HAE) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $35.83 (10.71% downside)

Analysts' Ratings History for Haemonetics (NYSE:HAE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Jefferies Group LLCReiterated RatingBuy$42.00MediumView Rating Details
2/7/2017Barrington ResearchDowngradeOutperform -> Market PerformN/AView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016Benchmark Co.Boost Price TargetHold$32.00 -> $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00N/AView Rating Details
5/16/2016Goldman Sachs Group IncUpgradeSell -> Neutral$29.00N/AView Rating Details
5/12/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
2/2/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
11/23/2015Raymond James Financial, Inc.DowngradeMarket Perform -> UnderperformN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Haemonetics (NYSE:HAE)
Earnings by Quarter for Haemonetics (NYSE:HAE)
Earnings History by Quarter for Haemonetics (NYSE:HAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Haemonetics (NYSE:HAE)
2017 EPS Consensus Estimate: $1.35
2018 EPS Consensus Estimate: $1.58
2019 EPS Consensus Estimate: $1.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.26$0.30$0.27
Q2 20173$0.29$0.34$0.32
Q3 20173$0.37$0.42$0.39
Q4 20173$0.35$0.38$0.36
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.43$0.47$0.44
Q4 20182$0.39$0.41$0.40
Q1 20191$0.25$0.25$0.25
Q2 20191$0.45$0.45$0.45
Q3 20191$0.47$0.47$0.47
Q4 20191$0.42$0.42$0.42
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Haemonetics (NYSE:HAE)
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 99.43%
Insider Trades by Quarter for Haemonetics (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)
Insider Trades by Quarter for Haemonetics (NYSE:HAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.90View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.18View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.72View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.68View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.14View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.61View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.98View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.44View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.18View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.00View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.26View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.00View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.00View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.80View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.22View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.00View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.00View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.66View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.00View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.00View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.00View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Haemonetics (NYSE:HAE)
Latest Headlines for Haemonetics (NYSE:HAE)
Source:
DateHeadline
bizjournals.com logoApheresis Equipment Market is expected to reach USD 3.7 billion by 2024
www.bizjournals.com - May 23 at 11:36 AM
finance.yahoo.com logoHaemonetics Sets Date for Investor / Analyst Meeting - June 19, 2017
finance.yahoo.com - May 22 at 5:10 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 20 at 12:12 AM
finance.yahoo.com logoHaemonetics Corp. – Value Analysis (NYSE:HAE) : May 19, 2017
finance.yahoo.com - May 19 at 5:21 PM
finance.yahoo.com logoHaemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : May 18, 2017
finance.yahoo.com - May 18 at 9:45 AM
americanbankingnews.com logoTheStreet Lowers Haemonetics Co. (HAE) to C
www.americanbankingnews.com - May 13 at 3:58 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Expected to Earn Q1 2019 Earnings of $0.25 Per Share
www.americanbankingnews.com - May 11 at 3:20 PM
americanbankingnews.com logoEquities Analysts Set Expectations for Haemonetics Co.'s FY2018 Earnings (HAE)
www.americanbankingnews.com - May 11 at 2:36 PM
americanbankingnews.com logoFY2018 Earnings Forecast for Haemonetics Co. (HAE) Issued By Jefferies Group
www.americanbankingnews.com - May 11 at 2:36 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Expected to Earn FY2018 Earnings of $1.59 Per Share
www.americanbankingnews.com - May 10 at 2:32 PM
americanbankingnews.com logoHaemonetics Co. (HAE) to Post Q1 2018 Earnings of $0.27 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 10 at 1:08 PM
americanbankingnews.com logoBarrington Research Equities Analysts Boost Earnings Estimates for Haemonetics Co. (HAE)
www.americanbankingnews.com - May 10 at 1:08 PM
americanbankingnews.com logoBrokers Offer Predictions for Haemonetics Co.'s Q1 2018 Earnings (HAE)
www.americanbankingnews.com - May 10 at 1:08 PM
finance.yahoo.com logoEdited Transcript of HAE earnings conference call or presentation 8-May-17 12:00pm GMT
finance.yahoo.com - May 10 at 12:35 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 9 at 5:02 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 8 at 10:16 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 8 at 8:56 PM
seekingalpha.com logoHaemonetics (HAE) Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:19 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 11:38 AM
finance.yahoo.com logoHaemonetics 4th Quarter and Fiscal Year 2017 Earnings Release and Fiscal Year 2018 Guidance Available on Investor Relations Website
finance.yahoo.com - May 8 at 8:15 AM
finance.yahoo.com logoHaemonetics reports 4Q loss
finance.yahoo.com - May 8 at 8:15 AM
seekingalpha.com logoHaemonetics beats by $0.01, beats on revenue
seekingalpha.com - May 8 at 6:25 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Haemonetics (HAE) Share Price
www.americanbankingnews.com - May 4 at 8:22 PM
americanbankingnews.com logoSomewhat Critical Press Coverage Very Likely to Affect Haemonetics (HAE) Share Price
www.americanbankingnews.com - May 1 at 3:42 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Expected to Announce Quarterly Sales of $221.08 Million
www.americanbankingnews.com - April 30 at 9:12 AM
finance.yahoo.com logo[$$] The Add-On Deal Roundup: April 28
finance.yahoo.com - April 28 at 8:38 PM
americanbankingnews.com logo Brokerages Anticipate Haemonetics Co. (HAE) to Post $0.37 EPS
www.americanbankingnews.com - April 28 at 1:44 PM
americanbankingnews.com logoHaemonetics (HAE) Given Daily Media Impact Score of 0.02
www.americanbankingnews.com - April 26 at 8:30 PM
finance.yahoo.com logoHaemonetics Sets Date for Publishing 4th Quarter and Full Fiscal Year 2017 Results and for Providing Fiscal 2018 Guidance: May 8, 2017
finance.yahoo.com - April 26 at 7:45 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 25 at 12:53 AM
americanbankingnews.com logoSomewhat Favorable Press Coverage Likely to Affect Haemonetics (HAE) Stock Price
www.americanbankingnews.com - April 23 at 10:01 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Raised to B- at TheStreet
www.americanbankingnews.com - April 19 at 8:44 PM
americanbankingnews.com logoHaemonetics (HAE) Given News Impact Rating of 0.13
www.americanbankingnews.com - April 18 at 12:34 AM
americanbankingnews.com logoHaemonetics Co. (HAE) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 9:00 AM
americanbankingnews.com logoHaemonetics Co. (HAE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 14 at 4:26 PM
americanbankingnews.com logoHaemonetics (HAE) Given Daily News Impact Score of 0.44
www.americanbankingnews.com - April 13 at 11:11 AM
finance.yahoo.com logoHaemonetics' Plasma Group Strong, Blood Center Group a Drag
finance.yahoo.com - April 12 at 5:41 PM
americanbankingnews.com logo Analysts Anticipate Haemonetics Co. (HAE) Will Post Earnings of $0.37 Per Share
www.americanbankingnews.com - April 7 at 5:35 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 4 at 1:23 PM
americanbankingnews.com logoHaemonetics Co. (HAE) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 30 at 1:41 PM
finance.yahoo.com logoWhy Is Haemonetics (HAE) Up 3.5% Since the Last Earnings Report?
finance.yahoo.com - March 9 at 4:25 AM
bizjournals.com logoApheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021
www.bizjournals.com - March 1 at 12:07 PM
finance.yahoo.com logoHAEMONETICS CORP Financials
finance.yahoo.com - February 10 at 6:19 PM
finance.yahoo.com logoQuotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer
finance.yahoo.com - February 9 at 6:28 PM
biz.yahoo.com logoHAEMONETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - February 8 at 6:15 PM
us.rd.yahoo.com logoHaemonetics downgraded by Barrington Research
us.rd.yahoo.com - February 7 at 11:56 PM
seekingalpha.com logoHaemonetics (HAE) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - February 7 at 3:40 AM
biz.yahoo.com logoHaemonetics Corp Earnings Call scheduled for 8:00 am ET today
biz.yahoo.com - February 6 at 10:39 PM
finance.yahoo.com logoEdited Transcript of HAE earnings conference call or presentation 6-Feb-17 1:00pm GMT
finance.yahoo.com - February 6 at 10:39 PM
us.rd.yahoo.com logoHaemonetics 3rd Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
us.rd.yahoo.com - February 6 at 5:39 PM

Social

Chart

Haemonetics (HAE) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff